CD8A and neoplasm: In lung cancer, that is sufficient to promote NK‐mediated regression [106], while in PDAC, the SASP increases tumour vascularization, facilitating chemotherapy delivery and efficacy, and increasing the recruitment of CD8+ T immune cells, thus sensitising these “cold” tumours to immunotherapy [242].